PCI Biotech and MDimune form research collaboration

OSLO, NORWAY: PCI Biotech, a Norwegian cancer focused biopharmaceutical company and MDimune Inc., a private South Korean biotech company developing innovative drug delivery technologies for modifying cellular and disease processes in many areas of human disease, announced a preclinical research collaboration that would offer several opportunities for future development. Commenting on the announcement, Per Walday,…

PCI Biotech forms research collaboration with DCprime

PCI Biotech forms research collaboration with DCprime

OSLO: PCI  Biotech has  announced an  extensive research collaboration. Within the  collaboration,  DCprime  and  PCI  Biotech  will combine their know-how and technology  platforms  to  pursue  the  development  of novel cancer vaccination concepts based on tumour-independent antigens (TIAs). PCI  Biotech  is  a  biopharmaceutical  late  stage clinical development company focusing  on  development  and  commercialisation  of  novel  therapies …